Rivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience

The “Dual-Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial

Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long-term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination with a platelet P2Y12 inhibitor (dual antiplatelet therapy [DAPT]) has become...

Novel oral anticoagulants for acute coronary syndrome.

Acute coronary syndrome (ACS) is a cardiovascular condition with a multifactorial pathophysiology that includes atherosclerotic plaques, platelet activation and thrombin production, among others. Thrombin production and the prothrombotic state of ACS patients have provided a role for anticoagulants to treat patients during the acute event and has led to subsequent research for the post-acute st...

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice

BACKGROUND Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome. METHODS In this double-blind, placebo-controlled trial, we randomly assigned 15,526 patients with ...

Rivaroxaban for preventing atherothrombotic events in people with acute coronary syndrome and elevated cardiac biomarkers: An Evidence Review Group perspective of a NICE Single Technology Appraisal Short Title: Rivaroxaban for acute coronary syndromes

Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.

Acute coronary syndrome (ACS) is a medical emergency. Patients who survive the initial event remain at risk of recurrent cardiovascular events. In most cases, ACS is triggered by thrombosis after rupture of an atherosclerotic plaque. Key to thrombus formation at this site is the generation of thrombin, which not only converts fibrinogen to fibrin but also serves as a potent platelet agonist and...